CD274 and renal cell carcinoma: In the phase III IMmotion010 trial, 778 patients with RCC with a clear cell or sarcomatoid component and increased risk of recurrence (T2 and grade 4, T3a and grade 3 or 4, T3b/T3c or T4 any grade, TxN+ and any grade, or M1 with no evidence of disease), 40% of whom were negative for PD-L1 expression, were randomized to receive atezolizumab 1200 mg or placebo every 3 weeks for 16 cycles or 1 year.